NEW YORK (GenomeWeb News) – The National Institutes of Health is seeking information about the barriers and challenges confronting the fields of pharmacogenomics and pharmacogenetics and it wants to hear suggestions about how to address them, the institute said in a request for information posted on its website on Friday.
To find out more about these challenges, NIH is inviting responses from the scientific community, pharmaceutical companies, federal agencies, and other parties. The agency also wants to hear “transformative ideas and approaches” about how to address the difficulties facing these new branches of medical science.
“Collectively, we want to identify ways in which NIH can effectively and efficiently address these barriers,” NIH said in the RFI. More specifically, the agency continued, the “best ideas will have great potential to dramatically affect how biomedical research is conducted over the next decade, yet will be concrete and achievable tasks.”
Examples of the type of ideas NIH is seeking include those that would address challenges that “no other entity is likely to be able to successfully conduct,” those that will generate publicly accessible knowledge, and those that clearly benefit public health.
The National Institute of General Medical Sciences will collect the suggestions on behalf of the Trans-NIH Pharmacogenomics Working Group. Suggestions are to be sent to the NIGMS website by April 30.